Your browser doesn't support javascript.
loading
Anti­HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano, Teizo; Ohishi, Tomokazu; Takei, Junko; Nakamura, Takuro; Nanamiya, Ren; Hosono, Hideki; Tanaka, Tomohiro; Sano, Masato; Harada, Hiroyuki; Kawada, Manabu; Kaneko, Mika K; Kato, Yukinari.
Afiliación
  • Asano T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Ohishi T; Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu­shi, Shizuoka 410­0301, Japan.
  • Takei J; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Nakamura T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Nanamiya R; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Hosono H; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Tanaka T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Sano M; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Harada H; Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo­ku, Tokyo 113­8510, Japan.
  • Kawada M; Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu­shi, Shizuoka 410­0301, Japan.
  • Kaneko MK; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
  • Kato Y; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980­8575, Japan.
Oncol Rep ; 46(2)2021 Aug.
Article en En | MEDLINE | ID: mdl-34184091
HER3 belongs to the epidermal growth factor receptor (EGFR) family and is known to form an active heterodimer with other three family members EGFR, HER2, and HER4. HER3 is overexpressed in lung, breast, colon, prostate, and gastric cancers. In the present study, we developed and validated an anti­HER3 monoclonal antibody (mAb), H3Mab­17 (IgG2a, kappa), by immunizing mice with HER3­overexpressed CHO­K1 cells (CHO/HER3). H3Mab­17 was found to react specifically with endogenous HER3 in colorectal carcinoma cell lines, using flow cytometry. The KD for H3Mab­17 in CHO/HER3 and Caco­2 (a colon cancer cell line) were determined to be 3.0x10­9 M and 1.5x10­9 M via flow cytometry, respectively, suggesting high binding affinity of H3Mab­17 to HER3. Then, we assessed the H3Mab­17 antibody­dependent cellular cytotoxicity (ADCC) and complement­dependent cytotoxicity (CDC) against Caco­2, and evaluated its antitumor capacity in a Caco­2 xenograft model. In vitro experiments revealed H3Mab­17 had strongly induced both ADCC and CDC against Caco­2 cells. In vivo experiments on Caco­2 xenografts revealed that H3Mab­17 treatment significantly reduced tumor growth compared with the control mouse IgG. These data indicated that H3Mab­17 could be a promising treatment option for HER3­expressing colon cancers.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Adenocarcinoma / Receptor ErbB-2 / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Oncol Rep Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Adenocarcinoma / Receptor ErbB-2 / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Oncol Rep Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón
...